Exploring the clinical potentials of zuranolone in managing postpartum depression: A new therapeutic horizon
<p>Postpartum depression (PPD) poses a major threat to maternal mental health and wellbeing while also adversely affecting the mother's relationship with her baby, leading to significant repercussions that may hinder the growth and cognitive development of the child. For decades, antidepr...
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | , , , |
| Published: |
2024
|
| Subjects: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1864513519861366784 |
|---|---|
| author | Abdulqadir J. Nashwan (11659453) |
| author2 | Syeda Tayyaba Rehan (16897080) Laiba Imran (16013039) Samina Ghulam Abbas (18192754) Sara Fahim Khan (18192757) |
| author2_role | author author author author |
| author_facet | Abdulqadir J. Nashwan (11659453) Syeda Tayyaba Rehan (16897080) Laiba Imran (16013039) Samina Ghulam Abbas (18192754) Sara Fahim Khan (18192757) |
| author_role | author |
| dc.creator.none.fl_str_mv | Abdulqadir J. Nashwan (11659453) Syeda Tayyaba Rehan (16897080) Laiba Imran (16013039) Samina Ghulam Abbas (18192754) Sara Fahim Khan (18192757) |
| dc.date.none.fl_str_mv | 2024-06-08T03:00:00Z |
| dc.identifier.none.fl_str_mv | 10.1016/j.pnpbp.2024.110983 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/journal_contribution/Exploring_the_clinical_potentials_of_zuranolone_in_managing_postpartum_depression_A_new_therapeutic_horizon/25449439 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Biomedical and clinical sciences Pharmacology and pharmaceutical sciences Psychology Biological psychology Postpartum depression Zuranolone GABAA Brexanolone |
| dc.title.none.fl_str_mv | Exploring the clinical potentials of zuranolone in managing postpartum depression: A new therapeutic horizon |
| dc.type.none.fl_str_mv | Text Journal contribution info:eu-repo/semantics/publishedVersion text contribution to journal |
| description | <p>Postpartum depression (PPD) poses a major threat to maternal mental health and wellbeing while also adversely affecting the mother's relationship with her baby, leading to significant repercussions that may hinder the growth and cognitive development of the child. For decades, antidepressants have been the mainstay of treating PPD; however, recent evidence suggests that antidepressants are not as effective as they are believed to be and there is a dire need to explore new treatment options. In 2023, a breakthrough in treating PPD emerged with the recent FDA approval of zuranolone, a gamma-aminobutyric acid (GABAA) receptor selective positive allosteric modulator. The implementation of zuranolone in treating PPD can prove to be revolutionary, considering it is the first oral medication available for PPD. Our review aims to discuss the various clinical trials that have been conducted to validate the efficacy of zuranolone in mitigating the symptoms of PPD, hence, leading to better outcomes for mothers.</p><h2>Other Information</h2> <p> Published in: Progress in Neuro-Psychopharmacology and Biological Psychiatry<br> License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1016/j.pnpbp.2024.110983" target="_blank">https://dx.doi.org/10.1016/j.pnpbp.2024.110983</a></p> |
| eu_rights_str_mv | openAccess |
| id | Manara2_ee2c04752271f71349dc107e13496f9b |
| identifier_str_mv | 10.1016/j.pnpbp.2024.110983 |
| network_acronym_str | Manara2 |
| network_name_str | Manara2 |
| oai_identifier_str | oai:figshare.com:article/25449439 |
| publishDate | 2024 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | Exploring the clinical potentials of zuranolone in managing postpartum depression: A new therapeutic horizonAbdulqadir J. Nashwan (11659453)Syeda Tayyaba Rehan (16897080)Laiba Imran (16013039)Samina Ghulam Abbas (18192754)Sara Fahim Khan (18192757)Biomedical and clinical sciencesPharmacology and pharmaceutical sciencesPsychologyBiological psychologyPostpartum depressionZuranoloneGABAABrexanolone<p>Postpartum depression (PPD) poses a major threat to maternal mental health and wellbeing while also adversely affecting the mother's relationship with her baby, leading to significant repercussions that may hinder the growth and cognitive development of the child. For decades, antidepressants have been the mainstay of treating PPD; however, recent evidence suggests that antidepressants are not as effective as they are believed to be and there is a dire need to explore new treatment options. In 2023, a breakthrough in treating PPD emerged with the recent FDA approval of zuranolone, a gamma-aminobutyric acid (GABAA) receptor selective positive allosteric modulator. The implementation of zuranolone in treating PPD can prove to be revolutionary, considering it is the first oral medication available for PPD. Our review aims to discuss the various clinical trials that have been conducted to validate the efficacy of zuranolone in mitigating the symptoms of PPD, hence, leading to better outcomes for mothers.</p><h2>Other Information</h2> <p> Published in: Progress in Neuro-Psychopharmacology and Biological Psychiatry<br> License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1016/j.pnpbp.2024.110983" target="_blank">https://dx.doi.org/10.1016/j.pnpbp.2024.110983</a></p>2024-06-08T03:00:00ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.1016/j.pnpbp.2024.110983https://figshare.com/articles/journal_contribution/Exploring_the_clinical_potentials_of_zuranolone_in_managing_postpartum_depression_A_new_therapeutic_horizon/25449439CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/254494392024-06-08T03:00:00Z |
| spellingShingle | Exploring the clinical potentials of zuranolone in managing postpartum depression: A new therapeutic horizon Abdulqadir J. Nashwan (11659453) Biomedical and clinical sciences Pharmacology and pharmaceutical sciences Psychology Biological psychology Postpartum depression Zuranolone GABAA Brexanolone |
| status_str | publishedVersion |
| title | Exploring the clinical potentials of zuranolone in managing postpartum depression: A new therapeutic horizon |
| title_full | Exploring the clinical potentials of zuranolone in managing postpartum depression: A new therapeutic horizon |
| title_fullStr | Exploring the clinical potentials of zuranolone in managing postpartum depression: A new therapeutic horizon |
| title_full_unstemmed | Exploring the clinical potentials of zuranolone in managing postpartum depression: A new therapeutic horizon |
| title_short | Exploring the clinical potentials of zuranolone in managing postpartum depression: A new therapeutic horizon |
| title_sort | Exploring the clinical potentials of zuranolone in managing postpartum depression: A new therapeutic horizon |
| topic | Biomedical and clinical sciences Pharmacology and pharmaceutical sciences Psychology Biological psychology Postpartum depression Zuranolone GABAA Brexanolone |